122 related articles for article (PubMed ID: 23781968)
1. Rapid worsening of IgM anti-MAG demyelinating polyneuropathy during rituximab treatment.
Stork AC; Notermans NC; Vrancken AF; Cornblath DR; van der Pol WL
J Peripher Nerv Syst; 2013 Jun; 18(2):189-91. PubMed ID: 23781968
[No Abstract] [Full Text] [Related]
2. Worsening after rituximab treatment in anti-mag neuropathy.
Broglio L; Lauria G
Muscle Nerve; 2005 Sep; 32(3):378-9. PubMed ID: 15986418
[No Abstract] [Full Text] [Related]
3. Beneficial effects of Rituximab in patients with anti-MAG (myelin-associated glycoprotein) neuropathy: case reports.
Souayah N; Noopur R; Tick-Chong PS
Immunopharmacol Immunotoxicol; 2013 Oct; 35(5):622-4. PubMed ID: 23944288
[TBL] [Abstract][Full Text] [Related]
4. Long-term response to rituximab and fludarabine combination in IgM anti-myelin-associated glycoprotein neuropathy.
Gruson B; Ghomari K; Beaumont M; Garidi R; Just A; Merle P; Merlusca L; Marolleau JP; Royer B
J Peripher Nerv Syst; 2011 Sep; 16(3):180-5. PubMed ID: 22003932
[TBL] [Abstract][Full Text] [Related]
5. Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy.
Kuijf ML; Eurelings M; Tio-Gillen AP; van Doorn PA; van den Berg LH; Hooijkaas H; Stork J; Notermans NC; Jacobs BC
Neurology; 2009 Sep; 73(9):688-95. PubMed ID: 19720975
[TBL] [Abstract][Full Text] [Related]
6. Acute neurological worsening after Rituximab treatment in patients with anti-MAG neuropathy.
Sala E; Robert-Varvat F; Paul S; Camdessanché JP; Antoine JC
J Neurol Sci; 2014 Oct; 345(1-2):224-7. PubMed ID: 25115501
[TBL] [Abstract][Full Text] [Related]
7. Neurophysiological and clinical responses to rituximab in patients with anti-MAG polyneuropathy.
Zara G; Zambello R; Ermani M
Clin Neurophysiol; 2011 Dec; 122(12):2518-22. PubMed ID: 21680240
[TBL] [Abstract][Full Text] [Related]
8. Deterioration of tremor after treatment with rituximab in anti-MAG neuropathy.
Doneddu PE; Kazmi M; Samuel M; Mahdi-Rogers M; Hadden RDM
J Neurol Sci; 2017 Feb; 373():344-345. PubMed ID: 28131219
[No Abstract] [Full Text] [Related]
9. Paradoxical worsening of anti–myelin-associated glycoprotein polyneuropathy following rituximab.
Weiss MD; Becker P
Muscle Nerve; 2014 Mar; 49(3):457-8. PubMed ID: 24741682
[No Abstract] [Full Text] [Related]
10. Antibodies to myelin-associated glycoprotein (anti-Mag) in IgM amyloidosis may influence expression of neuropathy in rare patients.
Garces-Sanchez M; Dyck PJ; Kyle RA; Zeldenrust S; Wu Y; Ladha SS; Klein CJ
Muscle Nerve; 2008 Apr; 37(4):490-5. PubMed ID: 18236455
[TBL] [Abstract][Full Text] [Related]
11. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy.
Dalakas MC; Rakocevic G; Salajegheh M; Dambrosia JM; Hahn AF; Raju R; McElroy B
Ann Neurol; 2009 Mar; 65(3):286-93. PubMed ID: 19334068
[TBL] [Abstract][Full Text] [Related]
12. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial.
Gorson KC; Natarajan N; Ropper AH; Weinstein R
Muscle Nerve; 2007 Jan; 35(1):66-9. PubMed ID: 16967492
[TBL] [Abstract][Full Text] [Related]
13. Nerve ultrasound findings in neuropathy associated with anti-myelin-associated glycoprotein antibodies.
Lucchetta M; Padua L; Granata G; Luigetti M; Campagnolo M; Dalla Torre C; Coraci D; Sabatelli M; Briani C
Eur J Neurol; 2015 Jan; 22(1):193-202. PubMed ID: 25174585
[TBL] [Abstract][Full Text] [Related]
14. [Rapid improvement by rituximab treatment in a case of demyelinating polyneuropathy with anti-myelin-associated glycoprotein antibody].
Motoyama R; Yamakawa K; Suzuki S; Kusunoki S; Tanaka M
Rinsho Shinkeigaku; 2011 Oct; 51(10):761-4. PubMed ID: 22019868
[TBL] [Abstract][Full Text] [Related]
15. High-dose rituximab and anti-MAG-associated polyneuropathy.
Renaud S; Fuhr P; Gregor M; Schweikert K; Lorenz D; Daniels C; Deuschl G; Gratwohl A; Steck AJ
Neurology; 2006 Mar; 66(5):742-4. PubMed ID: 16534115
[TBL] [Abstract][Full Text] [Related]
16. Clinical and laboratory features of anti-MAG neuropathy without monoclonal gammopathy.
Pascual-Goñi E; Martín-Aguilar L; Lleixà C; Martínez-Martínez L; Simón-Talero MJ; Díaz-Manera J; Cortés-Vicente E; Rojas-García R; Moga E; Juárez C; Illa I; Querol L
Sci Rep; 2019 Apr; 9(1):6155. PubMed ID: 30992531
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy of rituximab in IgM anti-myelin-associated glycoprotein neuropathy: RIMAG follow-up study.
Iancu Ferfoglia R; Guimarães-Costa R; Viala K; Musset L; Neil J; Marin B; Léger JM
J Peripher Nerv Syst; 2016 Mar; 21(1):10-4. PubMed ID: 26748872
[TBL] [Abstract][Full Text] [Related]
18. IgM deposits on skin nerves in anti-myelin-associated glycoprotein neuropathy.
Lombardi R; Erne B; Lauria G; Pareyson D; Borgna M; Morbin M; Arnold A; Czaplinski A; Fuhr P; Schaeren-Wiemers N; Steck AJ
Ann Neurol; 2005 Feb; 57(2):180-7. PubMed ID: 15668968
[TBL] [Abstract][Full Text] [Related]
19. [Monoclonal IgM autoantibody activity vis-à-vis glycoconjugates of peripheral nerves: apropos of 112 cases].
Caudie C; Vial C; Petiot P; Bancel J; Lombard C; Gonnaud PM
Ann Biol Clin (Paris); 2001; 59(5):567-77. PubMed ID: 11602387
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy-based regimen in anti-MAG neuropathy: results in 45 patients.
Hospital MA; Viala K; Dragomir S; Levy V; Cohen-Aubart F; Neil J; Musset L; Choquet S; Leger JM; Leblond V
Haematologica; 2013 Dec; 98(12):e155-7. PubMed ID: 24323988
[No Abstract] [Full Text] [Related]
[Next] [New Search]
